Table 2.
Comparison
|
miRNA
|
AUC
|
Sensitivity
|
Specificity
|
Ref.
|
HBV-carriers | miR-20a-5p | 0.770 | 0.866 | 0.573 | [231] |
HBV-carriers | miR-25-3p | 0.718 | 0.553 | 0.793 | [231] |
HBV-carriers | miR-30a-5p | 0.681 | 0.642 | 0.683 | [231] |
HBV-carriers | miR-92a-3p | 0.765 | 0.761 | 0.683 | [231] |
HBV-carriers | miR-132-3p | 0.722 | 0.910 | 0.366 | [231] |
HBV-carriers | miR-185-5p | 0.788 | 0.910 | 0.390 | [231] |
HBV-carriers | miR-320a | 0.678 | 0.388 | 0.878 | [231] |
HBV-carriers | miR-324-3p | 0.656 | 0.746 | 0.500 | [231] |
CHB | miR-26a | 0.650 | 0.533 | 0.833 | [30] |
CHB | miR-26a1 | 0.411 | 0.582 | 0.500 | [30] |
CHB | miR-27a | 0.761 | 0.677 | 0.833 | [30] |
CHB | miR-27a1 | 0.690 | 0.527 | 0.833 | [30] |
CHB | miR-34a | 0.619 | 0.400 | 0.870 | [21] |
CHB | miR-96 | 0.803 | 0.779 | 0.753 | [34] |
CHB | miR-99a2 | 0.694 | 0.844 | 0.567 | [232] |
CHB | miR-101 | 0.777 | 0.881 | 0.620 | [24] |
CHB | miR-122 | 0.190 | 0.250 | 0.250 | [16] |
CHB | miR-122 | 0.630 | 0.776 | 0.578 | [10] |
CHB | miR-125b | 0.675 | 0.522 | 0.867 | [30] |
CHB | miR-125b | 0.958 | 0.938 | 0.857 | [23] |
CHB | miR-125b | 0.792 | 0.906 | 0.567 | [232] |
CHB | miR-125b | 0.800 | 0.810 | 0.870 | [17] |
CHB | miR-125b1 | 0.631 | 0.400 | 0.870 | [30] |
CHB | miR-126 | 0.670 | 0.630 | 0.580 | [32] |
CHB | miR-142-3p | 0.550 | 0.320 | 0.910 | [32] |
CHB | miR-150 | 0.881 | 0.791 | 0.765 | [13] |
CHB | miR-214 | 0.520 | 0.850 | 0.430 | [21] |
CHB | miR-223 | 0.737 | 0.544 | 0.933 | [30] |
CHB | miR-2231 | 0.656 | 0.782 | 0.533 | [30] |
CHB | miR-224 | 0.846 | 0.865 | 0.745 | [11] |
CHB | miR-487b | 0.815 | 0.836 | 0.667 | [18] |
CHB | miR-487b | 0.856 | 0.759 | 0.897 | [19] |
CHB | miR-768-3p | 0.819 | 0.850 | 0.727 | [20] |
CHB | miR-5193 | 0.817 | 0.798 | 0.820 | [21] |
CHB | miR-6510 | 0.531 | 0.810 | 0.390 | [21] |
HBV-DN | let-7b | 0.633 | 0.825 | 0.467 | [233] |
HBV-DN | miR-122 | 0.648 | 0.667 | 0.567 | [233] |
HBV-LC | miR-26a-5p | 0.744 | 0.607 | 0.909 | [38] |
HBV-LC | miR-99a2 | 0.696 | 0.967 | 0.563 | [232] |
HBV-LC | miR-101 | 0.976 | 0.955 | 0.902 | [24] |
HBV-LC | miR-122 | 0.675 | 0.610 | 0.760 | [37] |
HBV-LC | miR-122-5p | 0.751 | 0.489 | 0.902 | [38] |
HBV-LC | miR-125b | 0.958 | 0.891 | 0.881 | [23] |
HBV-LC | miR-125b | 0.910 | 0.780 | 0.960 | [17] |
HBV-LC | miR-126 | 0.578 | 0.550 | 0.580 | [32] |
HBV-LC | miR-141-3p | 0.663 | 0.607 | 0.727 | [38] |
HBV-LC | miR-142-3p | 0.566 | 0.550 | 0.630 | [32] |
HBV-LC | miR-192-5p | 0.687 | 0.548 | 0.833 | [38] |
HBV-LC | miR-199a-5p | 0.589 | 0.593 | 0.576 | [38] |
HBV-LC | miR-205 | 0.781 | 0.969 | 0.542 | [36] |
HBV-LC | miR-206 | 0.693 | 0.778 | 0.689 | [38] |
HBV-LC | miR-224 | 0.832 | 0.865 | 0.667 | [11] |
HBV-LC | miR-433-5p | 0.644 | 0.564 | 0.674 | [38] |
HBV-LC | miR-1228-5p | 0.542 | 0.667 | 0.470 | [38] |
CHB + HBV-LC | miR-18a | 0.775 | 0.772 | 0.700 | [228] |
CHB + HBV-LC | miR-224 | 0.840 | 0.865 | 0.711 | [11] |
CHB + HBV-LC | miR-375 | 0.768 | 0.938 | 0.639 | [234] |
Comparing early-stage hepatitis B virus (HBV)-associated hepatocellular carcinoma (HCC) patients to patients with other stages.
Comparing advanced HBV-HCC to patients with other stages.
CHB: Chronic hepatitis B patient, HBV-DN: Hepatitis B virus-related dysplastic nodule patient; HBV-LC: Hepatitis B virus-related liver cirrhosis patient; AUC: Area under the receiver operating characteristic curve; miRNAs: MicroRNAs.